Chieh-Yu Lin, MD, PhD

Assistant Professor, Pathology & Immunology

Education

  • MD: National Taiwan University, Taipei, Taiwan (2009)
  • PhD, Philosophy: Stanford University, Stanford, CA (2014)
  • Residency, Anatomic Pathology: Stanford University, Stanford, CA (2017)
  • Fellowship, Breast Pathology: Stanford University, Stanford, CA (2017)
  • Fellowship, Molecular Genetic Pathology: Stanford University, Stanford, CA (2018)

Board Certifications

  • Anatomic Pathology, American Board of Pathology, 2017
  • Molecular Genetic Pathology, American Board of Pathology, 2018

Recognition

  • Alpha Omega Alpha Honor Medical Society

Clinical Interests

  • Breast Pathology
  • Cardiothoracic Pathology
  • Molecular Genetic Pathology

Research Interests

I am interested in understanding the genomic profiles of early neoplastic lesions in the breast. By incorporating traditional clinicopathologic risk factors and genomic predictors, I aim to develop and provide clinical prognostic tools for breast cancer patients. I am also interested in the pathogenesis and early detection of cardiac allograft vasculopathy, a leading cause of mortality in heart transplant patients.

Publications

Selected Publications

Lin CJ, Lin CY, Stitziela NO. Genetics of the Extracellular Matrix in Aortic Aneurysmal Diseases. Matrix Biology. Matrix Biol. 2018 Apr 12 [Epub ahead of print]
Lin CY, Mooney K, Choy W, Yang SR, Barry-Holson K, Horst K, Wapnir I, Allison H. Will Oncotype Dx DCIS Testing Guide Therapy? A Single Institution Correlation of Oncotype Dx DCIS Results with Histopathologic Findings and Clinical Management Decisions. Modern Pathology, 2018 Apr;31(4):562-568.
Yang SR, Lin CY, Stehr H, Long SR, Kong CS, Berry G, Zehnder JL, Kunder CA. Comprehensive genomic profiling of malignant effusions in patients with metastatic lung adenocarcinoma. Journal of Molecular Diagnostics. 2018 Mar;20(2):184-194.
Zhang BM, Aleshin A, Lin CY, Ford J, Zehnder JL, Suarez C. IDH2 mutation in a patient with metastatic colon cancer. New England Journal of Medicine. 2017; 376:1991-1992.
Lin CY, Carneal EE, Lichtensztajn DY, Gomez SL, Clarke CA, Jensen KC, Kurian AW, Allison KH. Regional variability in percent of breast cancers reported as positive for HER2 in California: implications of patient demographics on laboratory benchmarks. American Journal of Clinical Pathology. 2017 Sep 1;148(3):199-207.
Lin CY*, Barry-Holson K*, Allison KH. Breast Cancer stem cells: Are we ready to go from bench to bedside? Histopathology. 2016 Jan;68(1):119-37.
Van Nostrand JL, Brady CA, Jung H, Fuentes DR, Kozak MM, Johnson TM, Lin CY, Lin CJ, Swiderski DL, Vogel H, Bernstein JA, Attié-Bitach T, Chang CP, Wysocka J, Martin DM, Attardi LD. Inappropriate p53 activation during development induces features of CHARGE syndrome. Nature. 2014 Oct 9;514(7521):228-32.
Pei H, Li W, Lin CH, Yang J, Shang C, Nuernber S, Jin K, Xu W, Lin CY, Lin CJ, Xiong Y, Zhou B, Ashley E, Bernstein, D, Chen PS, Chen HS, Quertermous T, Chang CP. A long non-coding RNA protects the heart from pathological hypertrophy. Nature. 2014 Oct 2;514(7520):102-6.
Lin CY, Lin CJ, Chen CH, Chen RM, Zhou B, Chang CP. The secondary heart field is a new site of calcineurin/Nfatc1 signaling for semilunar valve development. J Mol Cell Cardiol. 2012 May;52(5):1096-102.
Lin CJ*, Lin CY*, Chen CH, Zhou B, Chang CP. Partitioning the heart: mechanisms of cardiac septation and valve development. Development. 2012 Sep;139(18):3277-99.

Assistant:
Keli Beckett
314-362-1329
kelibeckett@wustl.edu